Regenerative Medical Technology Group Inc. (RMTG)
| Market Cap | 1.13M +23.0% |
| Revenue (ttm) | 9.41M +94.3% |
| Net Income | -8.82M |
| EPS | -0.68 |
| Shares Out | 13.74M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50,747 |
| Open | 0.080032 |
| Previous Close | 0.0800 |
| Day's Range | 0.0791 - 0.0850 |
| 52-Week Range | 0.0189 - 0.1250 |
| Beta | 1.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 16, 2026 |
About RMTG
Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of stem cell therapies. The company is also involved in the treatment of patients; provision of training and seminars; and resale of kits, products, equipment, and services. In addition, it offers reoccurring application of its process using its kits and solutions. Further, it provides solutions from cli... [Read more]
Financial Performance
In 2025, RMTG's revenue was $5.10 million, an increase of 24.17% compared to the previous year's $4.11 million. Losses were -$7.81 million, 40.4% more than in 2024.
Financial StatementsNews
RMTG's Cellgenic Division Begins Local Commercial Activity in Colombia, Subject to Colombian Regulatory Requirements
Colombia is the third Latin American market in which Cellgenic has recently announced local commercial arrangements. Activity remains subject to applicable Colombian law and the terms of local contrac...
Cellgenic Establishes Local Commercial Presence in Brazil
Cellgenic is expanding local representation and commercial support in Brazil, one of Latin America's larger healthcare and aesthetic-medicine markets. ISSCA continues to hold physician-education event...
RMTG's Cellgenic Commences Commercial Activity in Peru, Extending Its Latin American Footprint
Peru becomes the newest addition to Cellgenic's Latin American commercial network - one of three coordinated market initiatives across the region, subject to applicable local regulatory requirements. ...
RMTG's Cellgenic Division Introduces MUSE Cell Product Line Across Four International Regions
A second cellular-technology launch in close succession broadens Cellgenic's portfolio into Latin America, the Middle East, Europe, and Southeast Asia, demonstrating a repeatable product-development m...
RMTG Acquires RMTG.com Domain and Launches New Investor-Focused Website, Advancing Shareholder Engagement
New Website Serves as a Central Source for Investor Information and Timely Disclosure; Investor Inquiries Directed to ir@rmtg.com MIAMI, FL / ACCESS Newswire / August 26, 2026 / Regenerative Medical T...
RMTG's Cellgenic Division Launches Natural Killer (NK) Cell Product Line for International Markets
New NK cell platform extends RMTG's cellular-technology portfolio into immunology-adjacent applications, with an initial commercial focus on Latin America and Southeast Asia. MIAMI, FL / ACCESS Newswi...
RMTG More Than Quadruples Revenue and Gross Profit in Q2 2026 Versus Q2 2025, With Operating Income Surpassing $560,000
Continued Acceleration in 2026 With Record Revenue, Expanding Margins, Growth in Operating Profit, and Accelerating Training and Product Supply Sales MIAMI, FL / ACCESS Newswire / August 20, 2026 / Re...
RMTG Provides Details for First-Ever Investor Call to Answer Shareholder Questions
Company Announces Date, Time and Connection Details for Its Inaugural Investor Call Following a Strong First Half of 2026 MIAMI, FL / ACCESS Newswire / August 19, 2026 / Regenerative Medical Technolog...
RMTG Expands Cellgenic's Cancún Laboratory Infrastructure with Two Additional ISO 7 Clean Rooms
An owned-infrastructure investment adds manufacturing, quality-systems, and product-development capacity to support Cellgenic's growing international product portfolio. MIAMI, FL / ACCESS Newswire / A...
RMTG to Hold First-Ever Investor Call to Discuss Second Quarter 2026 Results
A Positive First Half of 2026 Prompts the Company to Launch Its First Investor Call and Invite Shareholder Questions MIAMI, FL / ACCESS Newswire / August 5, 2026 / Regenerative Medical Technologies Gr...
RMTG Expands Cellgenic Operations Into Argentina, Establishing a Strategic Commercial Hub for Regenerative Medicine in Latin America
Cellgenic Launches Regulated Commercial Operations in Argentina, Creating a Platform for Biologics Distribution, Physician Education, and Regional Expansion Across Latin America MIAMI, FL / ACCESS New...
RMTG Launches ISSCA AI(TM) Clinical Intelligence Platform, Extending Its Global Regenerative Medicine Network Into AI-Driven Clinical Infrastructure
New AI Platform Builds on a 30+ Country Physician Network and the ISSCA Mobile App to Create a Connected, Technology-Enabled Ecosystem for Regenerative and Longevity Medicine MIAMI, FL / ACCESS Newswi...
Global Stem Cells Group (OTC:RMTG) Launches ISSCA Mobile App, Advancing Its Buildout of a Global Digital Ecosystem for Regenerative Medicine
New physician-facing platform digitizes a 30+ country network and lays the foundation for ISSCA AI™, positioning RMTG at the intersection of regenerative medicine and scalable health technology MIAMI,...
RMTG Surges 93% in Revenue, 87% in Gross Profit and 70% in Operating Income for Q1 2026 vs Q1 2025
Strong Start to 2026 With Record Revenue, Expanding Margins, Growth in Operating Profits and Accelerating Training and Product Supply Sales MIAMI, FL / ACCESS Newswire / June 10, 2026 / Regenerative M...
RMTG Subsidiary Cellgenic Commences Full-Scale Manufacturing at First-of-Its-Kind
Xeno-Free Biologics Facility in Cancún, Now Producing and Distributing Six Product Lines to International Markets COFEPRIS-Guided Laboratory Actively Shipping Exosomes, MSCs, NK Cells, and Allogeneic ...
RMTG Subsidiary CELLGENIC Introduces Peptide Pen Product Line at Cancún Global Summit
Pre-Loaded Synergistic Peptide Formulations Add New Revenue Stream Through Physician Distribution Network Spanning 30+ Countries LAS VEGAS, NEVADA / ACCESS Newswire / November 18, 2025 / Regenerative ...
RMTG Subsidiary CELLGENIC Expands into Dominican Republic with New Distribution Partnership
Strategic Caribbean Expansion Adds Revenue Opportunities Through Product Distribution and Physician Training Programs; ISSCA 2026 Event Planned for Q1 LAS VEGAS, NEVADA / ACCESS Newswire / October 21,...
RMTG Expands into Brazil with Strategic Representation Agreement
Julius Ladeira Appointed to Lead Market Entry into Latin America's Largest Healthcare Market; São Paulo Conference Scheduled for October 2-3, 2025 LAS VEGAS, NV / ACCESS Newswire / October 14, 2025 / ...
RMTG's ISSCA Regenerative Medicine Global Summit 2025 Concludes in Cancún with Full Attendance from 30+ Countries
Two-Day Event Features Scientific Sessions, Hands-On Workshops, and Soft Opening of CELLGENIC Manufacturing Laboratory LAS VEGAS, NEVADA / ACCESS Newswire / October 8, 2025 / Regenerative Medical Tech...
RMTG Partners with BKFC as Official Regenerative Medicine Provider
Combat Sports Partnership Brings Advanced Stem Cell Treatments to Elite Fighters LAS VEGAS, NEVADA / ACCESS Newswire / September 29, 2025 / Regenerative Medical Technologies Group, Inc. (the "Company"...
RMTG Subsidiary Cellgenic to Host Soft Opening of Advanced Cell Therapy Manufacturing Lab in Cancun During September ISSCA Global Summit
RMTG Subsidiary Cellgenic to Host Soft Opening of Advanced Cell Therapy Manufacturing Lab in Cancun During September ISSCA Global Summit COFEPRIS-Licensed Facility Positions Company for Full-Scale Ope...
RMTG Expands to Northern Argentina and Paraguay with New Affiliate Partnership
Former Minister of Health Brings Institutional Leadership to Expand Affiliate Network Across Key Latin American Markets LAS VEGAS, NV / ACCESS Newswire / July 29, 2025 / Regenerative Medical Technolog...
RMTG Expands to Puerto Rico with New Affiliate Partnership
Strategic Alliance Adds High-Value Territory to Global Network of 26 Clinics LAS VEGAS, NV / ACCESS Newswire / July 21, 2025 / Regenerative Medical Technologies Group, Inc. (OTC:RMTG), a global leader...
Regenerative Medical Technologies Group Increases Q1 2025 Sales By 67% Over Q1 2024 and Achieves Operating Profit for the Quarter of $134,000
Regenerative Medical Technologies Group, Inc. $RMTG, a regenerative medicine company, is pleased to announce that sales for its first quarter of 2025 surpassed $1.35M and achieved operational profits ...
Regenerative Medical Technology Group Announces the Opening of New Clinic in Dubai on November 23
RMTG is pleased to announce the opening of our newest clinic, located at the Hyatt Hotel in Jumeirah, UAE. LAS VEGAS, NV / ACCESSWIRE / November 7, 2024 / Regenerative Medical Technology Group Inc. $R...